Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-Label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer
Latest Information Update: 27 Jun 2023
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms Neo ALTTO
- Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharmaceuticals
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 27 Dec 2022 Results assessing 10-year event-free survival (EFS), overall survival (OS) and safety in HER2-positive breast cancer patients, published in the European Journal of Cancer.
- 18 Nov 2022 Results of an exploratory analysis assessing clinical outcome and feasibility using gene expression profile (GEP) samples from patients treated with L, T and L+T following two weeks of anti-HER2 therapy presented at the 13th European Breast Cancer Conference